Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00511316 · ClinicalTrials.gov registry record · Phase 1
Trial of Montelukast in Eosinophilic Esophagitis
A Phase 1 study, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT00511316: Completed Phase 1 study, sponsored by Mayo Clinic.
NCT00511316 is a Phase 1 study that has completed, run by Mayo Clinic. The registered enrollment target is 41 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00511316, a Phase 1 study, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
Evaluate clinical effectiveness of oral montelukast compared to placebo on prevention of dysphagia and food impaction in patients with EE. Also evaluate tolerance and safety of oral montelukast in treatment of EE.
Interventions
- DRUG Placebo
- DRUG Montelukast/ Singulair
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2007-08 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00511316
The ClinicalTrials.gov registry entry for NCT00511316 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00511316 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00511316 about?
NCT00511316 is a clinical study titled "Trial of Montelukast in Eosinophilic Esophagitis". Evaluate clinical effectiveness of oral montelukast compared to placebo on prevention of dysphagia and food impaction in patients with EE. Also evaluate tolerance and safety of oral montelukast in treatment of EE.
What is the current status of trial NCT00511316?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2007-08. Estimated completion is 2015-09.
What interventions are being tested in trial NCT00511316?
The interventions under investigation include: Placebo (DRUG), Montelukast/ Singulair (DRUG).
Who is sponsoring clinical trial NCT00511316?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.